FORM 4

Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden
hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	F F															
(Print or Type Responses) 1. Name and Address of Reporting Person* SIMON ROBERT L				2. Issuer Name and Ticker or Trading Symbol THRESHOLD PHARMACEUTICALS INC [THLD]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Officer (give title below) Senior Vice President				
(Last) (First) (Middle) C/O THRESHOLD PHARMACEUTICALS, INC., 170 HARBOR WAY, SUITE 300				3. Date of Earliest Transaction (Month/Day/Year) 02/26/2015								Senior	Vice Preside	ıt		
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(Cit		(State)	(Zip)			Ta	able I	- Non-De	rivative S	Securition	es Acquire	d, Disposed	of, or Benef	icially Owned	1	
1.Title of S (Instr. 3)	1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea		2A. Deemed Execution Date, if		ate, if C	(Instr. 8)		4. Securities Acqu (A) or Disposed c (Instr. 3, 4 and 5) (A) or Amount (D)		of (D) Ov Tra	5. Amount of Securities Be Owned Following Reported Transaction(s) (Instr. 3 and 4)		I I (Ownership	Beneficial Ownership	
Reminder:	Report on a s	separate line for each	class of securities b	eneficial	ly own	ned direc	tly or			rospon	d to the o	allaction of	informati	on contains	4 CEC	474 (0.02)
Reminder:	Report on a s	separate line for each		- Deriva	tive Se	ecurities	s Acqu	Person in this a curre	ns who in form are ently values	e not re lid OME or Bene	equired to 3 control of ficially Ow	respond ι number.		on containe form displa		474 (9-02)
1. Title of	2.	3. Transaction	Table II 3A. Deemed Execution Date, if	- Deriva (e.g., pu 4. Transact Code	tive Seats, cal 5. ion De Se Ac or (D (Ir	ecurities Ils, warr Number erivative ecurities cquired (s Acquerants,	Person in this a curre	form arently values of, onvertible ercisable Date	e not re lid OMI or Bene le secur	equired to 3 control of ficially Ow	o respond unumber. vned d Amount ving	8. Price of		10. Ownersh Form of Derivating Security Direct (I or Indire	11. Nature of Indire Beneficiae Ownersh (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction	Table II 3A. Deemed Execution Date, if any	- Deriva (e.g., pu 4. Transact Code	tive Seats, cal 5. ion De Se Ac or (D (Ir	Number erivative ecurities cquired (*Dispose D) nstr. 3, 4	s Acquerants,	Person in this a curroured, Dispoptions, c	ns who is form are not year to see the control of t	e not relid OMB	equired to 3 control ficially Owities) 7. Title an of Underly Securities	o respond unumber. vned d Amount ving	8. Price of Derivative Security	9. Number o Derivative Securities Beneficially Owned Following Reported	10. Ownersh Form of Derivating Security Direct (I or Indire	ip of Indire Beneficia Ownersh (Instr. 4)

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
SIMON ROBERT L C/O THRESHOLD PHARMACEUTICALS, INC. 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO, CA 94080			Senior Vice President			

Signatures

/s/ Joel A. Fernandes, Attorney-in-Fact	03/02/2015
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests in 48 equal monthly installments over a four-year period beginning on the date of grant of February 26, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.